Zacks: Analysts Expect Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Will Post Quarterly Sales of $22.97 Million

Wall Street brokerages expect Xeris Pharmaceuticals, Inc. (NASDAQ:XERS – Get Rating) to report sales of $22.97 million for the current quarter, according to Zacks. Four analysts have made estimates for Xeris Pharmaceuticals’ earnings. The highest sales estimate is $24.10 million and the lowest is $22.28 million. Xeris Pharmaceuticals posted sales of $8.05 million during the […]

Related Keywords

Chicago ,Illinois ,United States ,Steven Prestrelski ,Xeris Pharmaceuticals Inc ,Geode Capital Management ,Xeris Pharmaceuticals ,Zacks Investment Research ,Stonepine Capital Management ,Blackrock Inc ,Xeris Biopharma Holdings Inc ,Nasdaq ,Vanguard Group Inc ,Xeris Pharmaceuticals Get Rating ,Wall Street ,Get Rating ,Xeris Pharmaceutical ,Investment Research ,Capital Management ,Biopharma Holdings ,Nasdaq Xers ,Sixers ,Medical ,Ratings ,Consensus ,